- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02182310
Assessment of the Effect of BI 201335 on the QT Interval in Healthy Female and Male Subjects
July 17, 2014 updated by: Boehringer Ingelheim
Assessment of the Effect of 480 mg and 1200 mg of BI 201335 as Single Dose on the QT Interval in Healthy Female and Male Subjects. A Randomised, Placebo Controlled, Double-blind, Four-way Crossover Phase-I-study With Moxifloxacin as Positive Control
To demonstrate that BI 201335 does not prolong the QT interval more than placebo.
To assess the tolerability of 1200 mg of BI 201335 as single dose in female subjects (double-blind, randomised, placebo-controlled) before inclusion of female subjects in the cross-over part of the trial.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
56
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy caucasian males and females, 18 to 50 years of age
- Body mass index (BMI) ranging from 18.5 to 29.9 kg/m2 (BMI calculation: weight in kilograms divided by the square of height in meters)
- Signed written informed consent prior to admission to the study in accordance with Good Clinical Practice and the local legislation
Exclusion Criteria:
- Any finding of the medical examination (including blood pressure, pulse rate and electrocardiogram (ECG)) deviating from normal and of clinical relevance
- Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
- History of orthostatic hypotension, fainting spells or blackouts
- Chronic or relevant acute infections
- History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
- Intake of drugs with a long half-life (> 24 hours) within at least one month or less than 10 half-lives of the respective drug before enrolment in the study or during the study
- Use of any drugs which might influence the results of the trial up to 7 days prior to enrolment in the study or during the study
- Participation in another trial with an investigational drug (≤ 30 days prior to administration or during the trial)
- Heavy smoker (> 10 cigarettes or > 3 cigars of > 3 pipes/day)
- Inability to refrain from smoking on trial days
- Alcohol abuse (> 60 g/day)
- Drug abuse
- Blood donation (≥ 100 mL within four weeks prior to administration or during the trial)
- Any deviation of a laboratory value that is considered to be of clinical relevance
- Excessive physical activities within the last week before the trial or during the trial
- Hypersensitivity to BI 201335, moxifloxacin or related drugs of these classes
- Homozygous genotype status for "Gilbert" polymorphisms (Uridine diphosphate (UDP)-glucuronosyl transferase 1A1 (UGT1A1)*28, *60)
- Heart rate at screening of > 85 bpm or < 40 bpm
- Any screening ECG value outside of the reference range of clinical relevance including, but not limited to pulse rate (PR) interval > 220 ms, QRS interval > 115 ms, QTcB (QT interval, corrected for heart rate according to Bazett's formula) > 470 ms, or QT (uncorrected) > 470 ms
For Female subjects
- Pregnancy
- Positive pregnancy test
- No adequate contraception (adequate contraception e.g. sterilisation, intrauterine pressure , oral contraceptives). Females, who are not surgically sterile will be asked to additionally use barrier contraception methods (e.g. condom, diaphragm with spermicide)
- Inability to maintain this adequate contraception during the whole study period from the time of screening until one month after the last intake
- Lactation period
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
PLACEBO_COMPARATOR: BI 201335 placebo
crossover part
|
|
EXPERIMENTAL: BI 201335 low dose
crossover part
|
|
EXPERIMENTAL: BI 201335 high dose
crossover part
|
|
ACTIVE_COMPARATOR: Moxifloxacin
crossover part
|
|
EXPERIMENTAL: BI 201335 or Placebo
tolerability part in female subjects
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
QTcI interval (QT interval individually corrected for heart rate)
Time Frame: pre-dose and 3 to 8 hours
|
pre-dose and 3 to 8 hours
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The mean value of QTcI changes from baseline between 2 h and 24 h after dosing
Time Frame: Pre dose and 2 to 24 hours post dosing
|
Pre dose and 2 to 24 hours post dosing
|
The change from mean baseline of the QTcI at any point in time between 2 h and 24 h after dosing
Time Frame: Pre dose and 2 to 24 hours post dosing
|
Pre dose and 2 to 24 hours post dosing
|
The time-matched changes versus placebo in QTcI at any point in time between 2 h and 24 h after dosing
Time Frame: Pre dose and 2 to 24 hours post dosing
|
Pre dose and 2 to 24 hours post dosing
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2008
Primary Completion (ACTUAL)
October 1, 2008
Study Registration Dates
First Submitted
July 2, 2014
First Submitted That Met QC Criteria
July 7, 2014
First Posted (ESTIMATE)
July 8, 2014
Study Record Updates
Last Update Posted (ESTIMATE)
July 18, 2014
Last Update Submitted That Met QC Criteria
July 17, 2014
Last Verified
July 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1220.16
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Moxifloxacin
-
AiCuris Anti-infective Cures AGCompleted
-
Hoffmann-La RocheCompletedHealthy VolunteersUnited States
-
GlaxoSmithKlineCompletedInfluenza, HumanUnited States
-
University of California, San FranciscoRecruitingAntibiotic Resistance | Ocular Surface Microbiome | Gut ResistomeUnited States
-
CardioKine Inc.Biogen; Cardiokine Biopharma, LLCCompleted
-
Universidade Federal de PernambucoCompletedCataract | Endophthalmitis | Macula EdemaBrazil
-
Heidelberg UniversityBayerCompleted
-
University of KarachiCenter for Bioequivalence Studies and Clinical Research; SAMI Pharmaceutical...CompletedHealthy Individuals | Bioequivalence StudyPakistan
-
Lawson Health Research InstituteSt. Joseph's Healthcare FoundationCompletedAge-Related Macular DegenerationCanada
-
PfizerCompleted